SCHEMBL254952

SCHEMBL254952

Cc1ccc([S@@+]([O-])CC(=O)C(F)F)cc1

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.32
LMNA P02545 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
AGER Q15109 1/20 0.32
GSK3B P49841 1/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
MAPT P10636 1/20 0.31
ACHE P22303 1/20 0.31
KMT2A Q03164 3/20 0.31
MEN1 O00255 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 1/20 0.30
NPC1 O15118 2/20 0.30
RAB9A P51151 2/20 0.30
MDM2 Q00987 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30929941 0.78 KMT2A (0.41) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL9456923 0.78 KMT2A (0.41) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL9456919 0.78 KMT2A (0.41) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL254515 0.78 ALDH1A1 (0.37) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL9457024 0.78 KMT2A (0.41) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL9843695 0.77 ALDH1A1 (0.33) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL9843698 0.77 ALDH1A1 (0.33) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL255114 0.77 ALDH1A1 (0.33) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL3233200 0.76 CA2 (0.36) ALDH1A1LMNACES2CES1GSK3B
SCHEMBL30828001 0.74 TDP1 (0.41) ALDH1A1LMNAPOLBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349544-A1 Ethynylbenzene Derivatives DUKE UNIVERSITY 2017-12-07 US disclosed
US-20170349544-A1 Ethynylbenzene Derivatives DUKE UNIVERSITY 2017-12-07 US disclosed
US-9738604-B2 Ethynylbenzene derivatives DUKE UNIVERSITY (US) 2017-08-22 US disclosed
US-9738604-B2 Ethynylbenzene derivatives DUKE UNIVERSITY (US) 2017-08-22 US disclosed
US-20130231323-A1 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2013-09-05 US disclosed
US-20130231323-A1 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2013-09-05 US disclosed
WO-2012031298-A2 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349544-A1 Ethynylbenzene Derivatives Q6ZSR9, EPX, ZYX ALDH1A1 1651/4885LMNA 2493/4885CES2 1658/4885
US-20130231323-A1 ETHYNYLBENZENE DERIVATIVES Q6ZSR9, EPX, ZYX ALDH1A1 1651/4885LMNA 2493/4885CES2 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.